Search Results
Apr 21, 2026, 22:00 ET 邁威生物靶向Nectin-4 ADC（9MW2821）治療宮頸癌的病例報告登上《新英格蘭醫學雜誌》
患者繼續接受治療，後續影像學檢查提示肝臟病灶逐漸消退，長達兩年的隨訪，肝臟病灶未再出現。ADC藥物被譽為精準打擊腫瘤的「魔法子彈」。此前，「假性進展」多見於PD-1/PD-L1等免疫療法中，在實體瘤的ADC治療中堪稱「極為罕見」。汪善兵主任團隊的這一發現對晚期宮頸癌臨床治療具有重要指導意義。文章強有力地指出，切勿盲目因影像學「假象」而過早停止可能延長生命的治療，為ADC藥物的臨床應用提供了參考依據，切實守護腫瘤患者最佳治療獲益。9MW2821 是全球首款針對宮頸癌適應症進入III期臨床的Nectin-4 ADC創新藥。目前，單藥治療III期臨床已完成入組，計劃於2026年下半年進行期中分析，並根據期中分析結果向
More news about: 邁威生物
Apr 21, 2026, 22:00 ET Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
hailed as "magic bullets" for precisely targeting tumors. Previously, pseudoprogression has been predominantly observed in immunotherapies such as PD‑1/PD‑L1 inhibitors, whereas its occurrence in ADC therapy for solid tumors is considered exceedingly rare. This finding by Dr. Wang Shanbing's team carries
More news about: Mabwell
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
continue to determine the efficacy of MMV172 in the primate model of relapsing P. vivax malaria to develop an understanding of the anti-hypnozoite PK/PD relationship required to determine if MMV172 also meets the dose criterion for SERCAP (Single Encounter Radical Cure and Prophylaxis) or, if necessary,
More news about: GHIT Fund
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
continue to determine the efficacy of MMV172 in the primate model of relapsing P. vivax malaria to develop an understanding of the anti-hypnozoite PK/PD relationship required to determine if MMV172 also meets the dose criterion for SERCAP (Single Encounter Radical Cure and Prophylaxis) or, if necessary,
More news about: GHIT Fund
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
follows:Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 studyPresentation
More news about: Kelun-Biotech
Apr 21, 2026, 20:00 ET Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its first-in-class IBI363 (PD-1/IL-2α-biased bispecific fusion protein) * as well as TYVYT® (sintilimab injection)** will be presented at the 2026 American Society
More news about: Innovent Biologics
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
chemotherapy with or without the PD-1 inhibitor Tevimbra® (tislelizumab) in previously untreated HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), including a rapid oral presentation of analyses of progression-free survival (PFS) and overall survival (OS) across PD-L1 subgroups, as well as
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
modulate the tumor microenvironment, providing a mechanistic basis for the combination of golidocitinib with anti-PD-1/PD-L1 therapies in NSCLC patients who have progressed on prior anti-PD-1 containing regimens.Dr. Xiaolin Zhang, CEO of Dizal, said: "The new data to be reported at ASCO 2026 show
More news about: Dizal Pharmaceutical
Apr 21, 2026, 04:00 ET BrightCharger and Endrich sign licensing agreement to expand BrightZero® charging control to new components and products
worked with long-term determination to bring BrightZero into new USB-C PD charger categories, and Endrich gives us a strong channel to move that work into the component and OEM ecosystem. The upcoming BrightZero-enabled HT45F9160 PD Flash MCU is a concrete first step. By helping prevent unnecessary overcharging
More news about: BrightCharger OY
Apr 21, 2026, 04:00 ET BrightCharger und Endrich unterzeichnen Lizenzvereinbarung zur Erweiterung der BrightZero®-Ladesteuerung auf neue Komponenten und Produkte
Entschlossenheit daran gearbeitet, BrightZero in neue USB-C-PD-Ladegerätekategorien zu bringen, und Endrich gibt uns einen starken Kanal, um diese Arbeit in das Komponenten- und OEM-Ökosystem zu überführen. Die kommende BrightZero-enabled HT45F9160 PD Flash MCU ist ein konkreter erster Schritt. Indem sie unnötiges
More news about: BrightCharger OY
Apr 20, 2026, 22:54 ET Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
(9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented
More news about: Akeso, Inc.
Apr 20, 2026, 08:00 ET Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026
NCT05848739) is a first-in-human, open-label, Phase 1/2 dose escalation and expansion study designed to determine the safety, tolerability, PK, PD and early efficacy of ST316. The Phase 1 dose escalation portion of the study tested various dose levels of ST316 in patients with selected advanced
More news about: Sapience Therapeutics, Inc.
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more
More news about: Astellas Pharma Inc.
Apr 20, 2026, 04:17 ET Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
cytokine-based fusion proteins intended to unlock more precise immune modulation. Among the most advanced programs is FP008, a global first-in-class PD1 x IL10M fusion protein and potential next-generation backbone for cancer immunotherapy, with Phase I readout anticipated in 2026. Fapon Biopharma is
More news about: Fapon Biopharma
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
clearance, whereas the comparator BL-B01D1 showed no meaningful activity.7. Favorable PK/PD ProfileCS5007 demonstrated a superior pharmacokinetics (PK) / Pharmacodynamics (PD) profile compared to BL-B01D1 in the FaDu CDX model:Greater potency: At
More news about: CStone Pharmaceuticals
Apr 17, 2026, 22:38 ET 再鼎醫藥公布最新數據，顯示Zocilurtatug Pelitecan (Zoci) 在小細胞肺癌腦轉移患者中實現快速且顯著的顱內緩解，並在其他神經內分泌癌中展現出良好活性
pelitecan（zoci，前稱ZL-1310），在既往接受過治療的廣泛期小細胞肺癌（ES-SCLC）腦轉移患者中，經獨立評估采用改良版神經腫瘤腦轉移緩解評估（mRANO-BM）標准衡量，達到快速且顯著的顱內緩解，同時在其他神經內分泌癌（NECs）患者中顯示出有前景的數據。這些研究結果，以及ZL-6201（LRRC15 ADC）和ZL-1222（PD-1/IL-12）的臨床前數據，將在於聖地亞哥舉行的2026美國癌症研究協會（AACR）年會上公布。 一項正在進行的全球1期研究（NCT06179069）的結果表明，接受zoci治療可使腫瘤已轉移至大腦的ES-SCLC患者的顱內病灶顯著消退，該患者群體生存率低且缺乏有效治療選擇。西班牙馬德裡12 de Octubre大學醫院腫瘤內科主任、西班牙國家癌症研究中心（CNIO）肺癌單元負責人Luis
More news about: 再鼎醫藥
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
Poster Section 8Introduction: B7-H3 and PD-L1 are immune checkpoint molecules broadly overexpressed across multiple solid tumors and are associated with immune evasion and poor prognosis. Although PD-1/PD-L1-directed therapies have demonstrated clinical benefit, treatment
More news about: Antengene Corporation Limited
Apr 17, 2026, 15:00 ET Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small Cell Lung Cancer
NSCLC is the most common type of lung cancer, making up about 80% to 85% of all lung cancer cases. ICIs, including anti–PD–1 antibodies, are widely used as therapeutic agents for many types of cancer including lung cancer. While these treatments can produce significant benefits
More news about: Meiji Holdings Co Ltd
Apr 17, 2026, 15:00 ET Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.
More news about: Lunit
Apr 17, 2026, 15:00 ET Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
NST-628-001The ongoing Phase 1 open-label, single-arm, two-part study (NCT06326411) is investigating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of single-agent NST-628 in adult patients with RAS-MAPK pathway mutated/dependent advanced solid tumors, especially diverse
More news about: Nested Therapeutics Inc.
Apr 16, 2026, 10:00 ET ELEPHAS BIOSCIENCES AND MITHRL PAIR REAL-TIME TUMOR PROFILING WITH AGENTIC AI TO UNLOCK NEW IMMUNOTHERAPY RESPONSE INSIGHTS
multi-modal data analysis to generate biologically meaningful insights more efficiently.Poster Presentation: Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response (Abstract #5695) Date/Time: April 20, 2026, 9:00 AM - 12:00 PM PST Location: Section
More news about: Elephas
Apr 16, 2026, 08:00 ET DJI bietet Imaging-Funktionen der nächsten Generation mit der Osmo Pocket 4
sind wie folgt:Die Osmo Pocket 4 Standard Combo ist für 499 € erhältlich. Sie enthält die Osmo Pocket 4, ein USB-C-auf-USB-C-PD-Kabel (USB 3.1), die Osmo Pocket 4 Gimbal-Klemme, das DJI Armband, den Osmo Pocket 4 Griff mit 1/4″-Gewinde und den Osmo Pocket 4 tragbaren Tragebeutel.Die
More news about: DJI
Apr 16, 2026, 08:00 ET DJI offre des capacités d'imagerie de nouvelle génération avec Osmo Pocket 4
et configurations sont les suivants :Le bundle Standard Osmo Pocket 4 est vendu 499 EUR. Il comprend Osmo Pocket 4, un câble PD USB-C vers USB-C (USB 3.1), une pince de nacelle Osmo Pocket 4, une dragonne DJI, une poignée Osmo Pocket 4 avec filetage 1/4", et une pochette de transport
More news about: DJI
Apr 16, 2026, 08:00 ET Con Osmo Pocket 4 DJI offre funzionalità di imaging di nuova generazione
prezzi e le configurazioni sono i seguenti:L'Osmo Pocket 4 Combo Standard è in vendita a 499 EUR. Include Osmo Pocket 4, cavo PD da USB-C a USB-C (USB 3.1), morsetto per stabilizzatore Osmo Pocket 4, cinturino da polso DJI, manico con filettatura da 1/4″ per Osmo Pocket 4 e custodia
More news about: DJI
Apr 16, 2026, 08:00 ET DJI ofrece capacidades de captura de imágenes de última generación con Osmo Pocket 4
configuraciones son los siguientes:El pack Estándar Osmo Pocket 4 tiene un precio de 499 EUR. Incluye la Osmo Pocket 4, el cable PD USB-C a USB-C (USB 3.1), la abrazadera del estabilizador Osmo Pocket 4, la correa para la muñeca DJI, el asa Osmo Pocket 4 con rosca de 1/4″ y la funda
More news about: DJI